Omnicell, Inc. (NASDAQ: OMCL), which provides automation and business analytics solutions for medication and supply management, paid $275 million for Aesynt, a portfolio company of Francisco Partners. Aesynt, which Francisco only acquired in 2013, brings distinct capacities in dispensing systems, central pharmacy robotics, IV robotics and analytics. Aesynt’s robust medication management tools will complement Omnicell’s product portfolio and international footprint.
Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
